RecruitingAlzheimer DiseaseAgitation

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Eligible age

55–90 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

Sponsor: Bristol-Myers Squibb

You may qualify if…

✓ Participants must have completed study CN012-0023 or CN012-0024 per protocol.
✓ Participants must have one identified caregiver who should have sufficient contact (approximately 10 hours a week or more).

You may not qualify if…

✕ Participants must not have clinically significant cardiovascular (eg, untreated or unstable hypertension, clinically significant tachycardia), pulmonary, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
✕ Other protocol-defined Inclusion/Exclusion criteria apply.